Monday, 10 Dec 2018

You are here

Weight Loss Does Not Protect OA Knees

A new study presented at the Radiological Society of North America (RSNA) shows that obese people with substantial weight loss may significantly slow down the rate of joint space narrowing (cartilage degeneration) in the knee cartilage, but only if they lose weight through diet and exercise or diet alone; excercise alone is insufficient. 

Obesity is a major risk factor for osteoarthritis (OA), or acceleration of OA and ultimately the need for total knee replacement.

Gersing et al studied 760 patients from the from the Osteoarthritis Initiative who had a BMI >25 and had mild to moderate osteoarthritis.  Patients were divided into A) 380 patients who lost weight, and B) a control group of 380 patients who lost no weight.

Patients were followed for 8 years (96 mos) and studied according to how they achieved their weight loss : diet and exercise vs. diet alone and exercise alone. The researchers used MRI to quantify knee osteoarthritis at the beginning of the study, at 48 months and at 96 months.

Not surprisingly, cartilage loss was significantly less in the weight loss group, compared to the control group over the 96 months. However, this finding was only in those who lost weight through diet and exercise or diet alone.

Weight loss through exercise alone showed no significant difference in cartilage degeneration, compared to the group who lost no weight.

Weight loss has been shown to slow down cartilage degeneration in overweight and obese individuals, but it was unclear if the method used to lose weight made a difference.

These findings suggest that a comprehensive approach to weight loss may be needed to protect OA knees from further damage.  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Dendrimer Nanocarrier Delivers IGF-1 to Degenerative Cartilage

Researchers from MIT have developed a novel treatment for osteoarthritis (OA) by using dendrimer-based nanocarriers to deliver insulin-like growth factor 1 (IGF-1) to chondrocytes within joint cartilage and in animal models have shown when these nanocarriers injected into rat knees in models of OA, they reduced cartilage degeneration.

Low Risk of Serious Complications with Meniscectomy

Lancet reports on the safety of over 1 million arthroscopic partial meniscectomies done in the United Kingdom and found a low overall risk in the first 90 days. They examined Hospital Episode Statistics on  1,088,782 arthroscopic partial meniscectomies (1997-2017); 699 965 of which were eligible for analysis. They sought to identify complications occurring in the 90 days after the index procedure.

Pre-Diabetes Associated Risk for Arthritis, Obesity and Physical Inactivity

The current MMWR reports that arthritis is seen in nearly one-third of adults with prediabetes and that more than half of such patients are obese and not engaged in regular physical activity.

Doctor-diagnosed arthritis affects 54.4 million in the U.S. and the CDC expects this to rise to 78.4 million by 2040.

Controversial New Super Opioid Approved by FDA

Amidst a new DEA report demonstrating a record number of opioid overdose deaths (n-72,000 or ~ 200 deaths per day), the FDA has approved a newer and far more potent opioid than those that are currently being abused at alarming rates. The new agent is named Dsuvia.

Late Breaker: Can Tanezumab Be Revived for OA?

The monoclonal antibody tanezumab, which blocks nerve growth factor, showed significant benefits in pain and function among patients with osteoarthritis (OA) of the knee or hip, and rates of severe adverse joint events such as rapidly progressive OA that had plagued earlier studies were low, a researcher reported at the annual meeting of the American College of Rheumatology in Chicago last week.